Addus HomeCare's stock plummeted 5.61% during intraday trading on Tuesday, following negative analyst actions that weighed on investor sentiment.
The decline came after Barclays maintained its Sell rating on the company with a price target of $102.00. Additionally, Bofa Global Research cut its price objective for Addus HomeCare to $140.00 from $147.00, contributing to the downward pressure on the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.